| Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation (NCT06970132) | Shouyao Holdings (Beijing) Co. LTD | 2025-06-01 |
| A Study to Evaluate the Mass Balance of [14C] SY-5007 in Healthy Adult Male Subjects in China (NCT06352190) | Shouyao Holdings (Beijing) Co. LTD | 2024-05-01 |
| A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC (NCT06254599) | Shouyao Holdings (Beijing) Co. LTD | 2024-05-01 |
| A Study to Evaluate the Food Effects on Pharmacokinetics of SY-5007 Tablets in Healthy Subjects (NCT06325761) | Shouyao Holdings (Beijing) Co. LTD | 2024-04-01 |
| A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SY-5007 in Healthy Subjects (NCT06332053) | Shouyao Holdings (Beijing) Co. LTD | 2024-04-01 |
| Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC (NCT06031558) | Shouyao Holdings (Beijing) Co. LTD | 2023-10-31 |
| A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation (NCT06006793) | Shouyao Holdings (Beijing) Co. LTD | 2023-08-10 |
| Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI (NCT05869162) | Shouyao Holdings (Beijing) Co. LTD | 2023-06-30 |
| Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer (NCT05580445) | Shouyao Holdings (Beijing) Co. LTD | 2022-08-11 |
| A Phase I Study of SY-4835 in Patients With Advanced Solid Tumors (NCT05291182) | Shouyao Holdings (Beijing) Co. LTD | 2021-06-28 |
| Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor (NCT05278364) | Shouyao Holdings (Beijing) Co. LTD | 2021-04-23 |
| Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer (NCT05257512) | Shouyao Holdings (Beijing) Co. LTD | 2020-04-26 |